Zydus Cadila's Q3 net up 41% to Rs 527 cr on strong India biz growth

US formulations business dips 4% with revenues at Rs 1,603 cr, Q3 sees Zydus file 10 additional ANDAs with US FDA, taking total filings to 410

Led by double-digit growth in its India business, Ahmedabad-based drug maker Cadila Healthcare Ltd (Zydus Cadila) has seen its consolidated net profit rise 41 per cent at Rs 527.2 crore in the third quarter ended December 30, 2020.

The company's consolidated net profit was Rs 373.9 crore in the same period last year. Consolidated revenue from operations grew 6.2 per cent in Q3 of FY21 to Rs 3753.7 crore, from Rs 3,534.5 crore a year ago.

The company's business in India consisting of human health formulations, consumer wellness and animal health grew 20 per cent year-on-year (YoY) during the quarter,